

CORRECTION

Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Stephanie I. Kim, Andy H. Szeto, Katherine P. Morgan, Blaine Brower, Mary W. Dunn, Amir H. Khandani, Paul A. Godley, Tracy L. Rose, Ethan M. Basch, Matthew I. Milowsky, Young E Whang, Daniel J Crona

The following information is missing from the Funding statement: The authors would also like to gratefully acknowledge support provided by the Willis H. Thompson Prostate Cancer Research Fund. The publisher apologizes for the error.

The co-corresponding authors, Young E. Whang and Daniel J. Crona, should be noted as contributing equally to this work.

There are errors in the Author Contributions. The correct contributions are:

Conceptualization: Stephanie I. Kim, Andy H. Szeto, Young E. Whang, Daniel J. Crona.

Data curation: Stephanie I. Kim, Andy H. Szeto, Young E. Whang, Daniel J. Crona.

Formal analysis: Stephanie I. Kim, Andy H. Szeto, Young E. Whang, Daniel J. Crona.

Investigation: Stephanie I. Kim, Katherine P. Morgan, Blaine Brower, Mary W. Dunn, Amir H. Khandani, Paul A. Godley, Tracy L. Rose, Ethan M. Basch, Matthew I. Milowsky, Young E. Whang, Daniel J. Crona.

Project administration: Young E. Whang, Daniel J. Crona.

Resources: Young E. Whang, Daniel J. Crona.


Supervision: Young E. Whang, Daniel J. Crona.

Writing—original draft: Stephanie I. Kim, Andy H. Szeto, Katherine P. Morgan, Blaine Brower, Mary W. Dunn, Amir H. Khandani, Tracy L. Rose, Ethan M. Basch, Matthew I. Milowsky, Young E. Whang, Daniel J. Crona.

Writing—review & editing: Stephanie I. Kim, Andy H. Szeto, Katherine P. Morgan, Blaine Brower, Mary W. Dunn, Amir H. Khandani, Tracy L. Rose, Ethan M. Basch, Matthew I. Milowsky, Young E. Whang, Daniel J. Crona.

Reference

1. Kim SI, Szeto AH, Morgan KP, Brower B, Dunn MW, Khandani AH, et al. (2021) A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. PLoS ONE 16(6): e0253021. <https://doi.org/10.1371/journal.pone.0253021> PMID: 34153052



OPEN ACCESS

Citation: Kim SI, Szeto AH, Morgan KP, Brower B, Dunn MW, Khandani AH, et al. (2021) Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. PLoS ONE 16(12): e0262326. <https://doi.org/10.1371/journal.pone.0262326>

Published: December 31, 2021

Copyright: © 2021 Kim et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.